Asked by Hana
What is LDL and HDL cholesterol (explain deeply)
All Answers 1
Answered by
GPT-5 mini
AI
Short answer up front
- LDL (low-density lipoprotein) and HDL (high-density lipoprotein) are classes of blood lipoprotein particles that carry cholesterol and other lipids. They have very different roles: LDL delivers cholesterol to tissues (including artery walls) and is the main driver of atherosclerosis when present in excess; HDL participates in reverse cholesterol transport (moving cholesterol away from tissues toward the liver) and has several anti-atherogenic functions. Both are complex particles whose number, composition and function determine cardiovascular risk.
Why lipoproteins exist
- Cholesterol and triglycerides are insoluble in water. The body packages them into lipoprotein particles made of a hydrophobic core (triglycerides and cholesteryl esters) surrounded by a surface monolayer of phospholipids, free cholesterol and apolipoproteins. Apolipoproteins stabilize the particle and interact with enzymes and receptors.
Basic structure and key apolipoproteins
- Core: triglycerides and cholesteryl esters.
- Surface: phospholipids, free cholesterol.
- Important apolipoproteins:
- ApoB100: structural protein of VLDL, IDL and LDL (one ApoB100 per particle). ApoB is a proxy for the number of atherogenic particles.
- ApoA-I: main structural protein of HDL.
LDL — detailed
- What it is: LDL is derived mainly from the metabolic remodeling of VLDL (very-low-density lipoprotein). It carries cholesterol (mostly as cholesteryl esters) and delivers it to peripheral cells.
- Size/composition: relatively cholesterol-rich, single ApoB100 per particle.
- Cellular uptake: LDL binds to LDL receptors (LDLR) on cells via ApoB100; particles are taken up by receptor-mediated endocytosis and cholesterol is released intracellularly.
- Role in disease: Elevated LDL particles promote atherosclerosis. LDL particles that enter the arterial intima can be modified (oxidized, aggregated) and taken up by macrophage scavenger receptors, forming foam cells and initiating plaque formation.
- Atherogenicity: Depends on particle number (ApoB), cholesterol per particle (LDL-C), and particle quality. Small, dense LDL is more atherogenic than large, buoyant LDL because it penetrates the arterial wall more readily and is more easily oxidized.
- Genetics/clinical syndromes: Familial hypercholesterolemia (mutations in LDLR, ApoB, or gain-of-function PCSK9) causes very high LDL and early cardiovascular disease.
HDL — detailed
- What it is: HDL particles are smaller and denser, carry ApoA-I, and are central to reverse cholesterol transport (RCT).
- Reverse cholesterol transport: HDL collects excess cholesterol from peripheral cells (including macrophage foam cells) via transporters such as ABCA1 and ABCG1. LCAT (lecithin–cholesterol acyltransferase) esterifies free cholesterol on HDL to form cholesteryl esters that move into the HDL core, allowing HDL to carry more cholesterol.
- Interactions: HDL can transfer cholesteryl esters to apoB-containing lipoproteins (LDL/VLDL) via CETP (cholesteryl ester transfer protein) in exchange for triglycerides; this can indirectly route cholesterol to the liver.
- Other functions: antioxidant (preventing LDL oxidation), anti-inflammatory, antithrombotic, endothelial-protective. Much of HDL’s protective effect depends on its function and composition, not just its concentration.
- Complexity: HDL particles are heterogeneous in size, composition and function. Higher HDL-C concentrations are epidemiologically associated with lower cardiovascular risk, but pharmacologic raising of HDL-C (e.g., some CETP inhibitors or niacin) has not reliably reduced cardiovascular events, suggesting HDL functionality is key.
How these particles are formed and metabolized (process overview)
- Liver synthesizes VLDL (triglyceride-rich), which delivers triglycerides to tissues via the action of lipoprotein lipase (LPL). As VLDL loses triglycerides it becomes IDL and then LDL.
- LDL is cleared mainly by the hepatic LDL receptor (binding ApoB100).
- HDL particles are formed in the liver/intestine as nascent, discoidal HDL (ApoA-I + phospholipids); they accept cholesterol from cells (via ABCA1), get esterified by LCAT and mature into spherical HDL. HDL delivers cholesterol to the liver directly via SR-BI receptor or indirectly via CETP-mediated transfer to LDL/VLDL.
Pathophysiology of atherosclerosis (how LDL causes disease)
- Excess LDL particles in plasma → more LDL enters intima of arteries.
- LDL becomes retained and modified (oxidized, aggregated) → triggers inflammation.
- Macrophages take up modified LDL via scavenger receptors → become foam cells.
- Foam cells and ongoing inflammation form fatty streaks, fibrous plaques, and eventually unstable plaques that can rupture and cause myocardial infarction or stroke.
- HDL helps remove cholesterol from macrophages and has anti-inflammatory/antioxidant roles that counter these processes.
Clinical measurement and interpretation
- Common lab tests:
- Total cholesterol (TC)
- LDL cholesterol (LDL-C): often calculated by Friedewald formula: LDL-C = TC − HDL-C − (TG/5) [mg/dL], requires fasting and is inaccurate when triglycerides (TG) are high (>400 mg/dL). Direct LDL assays or newer equations (e.g., Martin-Hopkins) can be used.
- HDL cholesterol (HDL-C)
- Triglycerides (TG)
- Non-HDL cholesterol = TC − HDL-C (captures all atherogenic particles)
- ApoB (direct measure of number of atherogenic particles) and Lp(a) (an LDL-like particle with Apo(a)) are increasingly used.
- Units: mg/dL (USA) and mmol/L (international). Conversion for cholesterol: 1 mmol/L ≈ 38.67 mg/dL.
- Typical targets (guideline-dependent):
- LDL-C: desirable <100 mg/dL (2.6 mmol/L); for high-risk patients (e.g., known ASCVD) many guidelines aim for <70 mg/dL (1.8 mmol/L) or lower with intensive therapy.
- HDL-C: higher is generally better; low HDL-C is <40 mg/dL (men) and <50 mg/dL (women). But HDL-C is not usually a primary treatment target — focus is on lowering LDL and reducing overall risk.
- Non-HDL and ApoB are useful when triglycerides are elevated.
Advanced/nuanced points
- Particle number vs cholesterol content: Two people can have the same LDL-C but different numbers of LDL particles. ApoB or LDL particle number (by NMR) predict risk better than LDL-C in some cases.
- Small dense LDL: more atherogenic; often associated with high TG and low HDL (atherogenic dyslipidemia), common in insulin resistance/type 2 diabetes.
- HDL functionality: antioxidant, cholesterol efflux capacity (a functional assay) may predict risk better than HDL-C level. Attempts to raise HDL-C pharmacologically have largely failed to reduce events because simply raising HDL-C does not guarantee improved function.
- Remnant cholesterol: cholesterol carried by triglyceride-rich remnants (VLDL remnants/IDL) also contributes to atherosclerosis.
- Lp(a): an LDL-like particle with an extra Apo(a) protein; genetically determined and an independent risk factor.
How drugs affect LDL and HDL (brief)
- Statins: inhibit HMG-CoA reductase → lower hepatic cholesterol synthesis → upregulate LDL receptors → lower LDL-C (primary therapy for reducing CV events).
- PCSK9 inhibitors (monoclonal antibodies, siRNA): block PCSK9-mediated LDLR degradation → more LDL receptors → large LDL-C reductions.
- Ezetimibe: reduces intestinal cholesterol absorption → lowers LDL-C (often added to statin).
- Bile acid sequestrants: lower LDL-C by interrupting bile acid reabsorption.
- Fibrates: primarily lower triglycerides and can modestly raise HDL; used for hypertriglyceridemia.
- Niacin: raises HDL-C and lowers LDL-C/TG but trials did not show consistent cardiovascular benefit when added to statins and side effects limit use.
- CETP inhibitors: raised HDL-C substantially in some cases but mostly failed to reduce events (except anacetrapib lowered events in some analyses), again highlighting HDL complexity.
Lifestyle effects
- Diet: saturated and trans fats raise LDL; replacing saturated fats with polyunsaturated fats lowers LDL. Dietary cholesterol has modest effects in most people. Reducing refined carbs and weight loss helps triglycerides and HDL.
- Exercise: aerobic exercise modestly raises HDL and improves HDL function.
- Weight loss: lowers LDL and TG and raises HDL.
- Smoking: lowers HDL and increases cardiovascular risk.
- Alcohol: moderate intake can raise HDL, but benefits are offset by other risks and not advised as a preventive strategy.
Takeaway summary
- LDL and HDL are lipoprotein particles that carry cholesterol but have very different roles: LDL delivers cholesterol (and in excess causes atherosclerosis), HDL participates in removing cholesterol and has protective functions. Cardiovascular risk is driven mainly by the number and quality of atherogenic particles (LDL, VLDL remnants, Lp[a]), with ApoB and non-HDL often better integrative measures than LDL-C alone. Clinical management focuses primarily on lowering LDL to reduce cardiovascular events; HDL-C levels are less useful as a therapeutic target than once thought because HDL function matters more than concentration.
If you want, I can:
- Explain the biochemical pathways in more molecular detail (e.g., specific enzymes, receptors and genes).
- Show how to interpret a lipid panel with example numbers.
- Summarize current guideline LDL targets for a particular risk category.
- LDL (low-density lipoprotein) and HDL (high-density lipoprotein) are classes of blood lipoprotein particles that carry cholesterol and other lipids. They have very different roles: LDL delivers cholesterol to tissues (including artery walls) and is the main driver of atherosclerosis when present in excess; HDL participates in reverse cholesterol transport (moving cholesterol away from tissues toward the liver) and has several anti-atherogenic functions. Both are complex particles whose number, composition and function determine cardiovascular risk.
Why lipoproteins exist
- Cholesterol and triglycerides are insoluble in water. The body packages them into lipoprotein particles made of a hydrophobic core (triglycerides and cholesteryl esters) surrounded by a surface monolayer of phospholipids, free cholesterol and apolipoproteins. Apolipoproteins stabilize the particle and interact with enzymes and receptors.
Basic structure and key apolipoproteins
- Core: triglycerides and cholesteryl esters.
- Surface: phospholipids, free cholesterol.
- Important apolipoproteins:
- ApoB100: structural protein of VLDL, IDL and LDL (one ApoB100 per particle). ApoB is a proxy for the number of atherogenic particles.
- ApoA-I: main structural protein of HDL.
LDL — detailed
- What it is: LDL is derived mainly from the metabolic remodeling of VLDL (very-low-density lipoprotein). It carries cholesterol (mostly as cholesteryl esters) and delivers it to peripheral cells.
- Size/composition: relatively cholesterol-rich, single ApoB100 per particle.
- Cellular uptake: LDL binds to LDL receptors (LDLR) on cells via ApoB100; particles are taken up by receptor-mediated endocytosis and cholesterol is released intracellularly.
- Role in disease: Elevated LDL particles promote atherosclerosis. LDL particles that enter the arterial intima can be modified (oxidized, aggregated) and taken up by macrophage scavenger receptors, forming foam cells and initiating plaque formation.
- Atherogenicity: Depends on particle number (ApoB), cholesterol per particle (LDL-C), and particle quality. Small, dense LDL is more atherogenic than large, buoyant LDL because it penetrates the arterial wall more readily and is more easily oxidized.
- Genetics/clinical syndromes: Familial hypercholesterolemia (mutations in LDLR, ApoB, or gain-of-function PCSK9) causes very high LDL and early cardiovascular disease.
HDL — detailed
- What it is: HDL particles are smaller and denser, carry ApoA-I, and are central to reverse cholesterol transport (RCT).
- Reverse cholesterol transport: HDL collects excess cholesterol from peripheral cells (including macrophage foam cells) via transporters such as ABCA1 and ABCG1. LCAT (lecithin–cholesterol acyltransferase) esterifies free cholesterol on HDL to form cholesteryl esters that move into the HDL core, allowing HDL to carry more cholesterol.
- Interactions: HDL can transfer cholesteryl esters to apoB-containing lipoproteins (LDL/VLDL) via CETP (cholesteryl ester transfer protein) in exchange for triglycerides; this can indirectly route cholesterol to the liver.
- Other functions: antioxidant (preventing LDL oxidation), anti-inflammatory, antithrombotic, endothelial-protective. Much of HDL’s protective effect depends on its function and composition, not just its concentration.
- Complexity: HDL particles are heterogeneous in size, composition and function. Higher HDL-C concentrations are epidemiologically associated with lower cardiovascular risk, but pharmacologic raising of HDL-C (e.g., some CETP inhibitors or niacin) has not reliably reduced cardiovascular events, suggesting HDL functionality is key.
How these particles are formed and metabolized (process overview)
- Liver synthesizes VLDL (triglyceride-rich), which delivers triglycerides to tissues via the action of lipoprotein lipase (LPL). As VLDL loses triglycerides it becomes IDL and then LDL.
- LDL is cleared mainly by the hepatic LDL receptor (binding ApoB100).
- HDL particles are formed in the liver/intestine as nascent, discoidal HDL (ApoA-I + phospholipids); they accept cholesterol from cells (via ABCA1), get esterified by LCAT and mature into spherical HDL. HDL delivers cholesterol to the liver directly via SR-BI receptor or indirectly via CETP-mediated transfer to LDL/VLDL.
Pathophysiology of atherosclerosis (how LDL causes disease)
- Excess LDL particles in plasma → more LDL enters intima of arteries.
- LDL becomes retained and modified (oxidized, aggregated) → triggers inflammation.
- Macrophages take up modified LDL via scavenger receptors → become foam cells.
- Foam cells and ongoing inflammation form fatty streaks, fibrous plaques, and eventually unstable plaques that can rupture and cause myocardial infarction or stroke.
- HDL helps remove cholesterol from macrophages and has anti-inflammatory/antioxidant roles that counter these processes.
Clinical measurement and interpretation
- Common lab tests:
- Total cholesterol (TC)
- LDL cholesterol (LDL-C): often calculated by Friedewald formula: LDL-C = TC − HDL-C − (TG/5) [mg/dL], requires fasting and is inaccurate when triglycerides (TG) are high (>400 mg/dL). Direct LDL assays or newer equations (e.g., Martin-Hopkins) can be used.
- HDL cholesterol (HDL-C)
- Triglycerides (TG)
- Non-HDL cholesterol = TC − HDL-C (captures all atherogenic particles)
- ApoB (direct measure of number of atherogenic particles) and Lp(a) (an LDL-like particle with Apo(a)) are increasingly used.
- Units: mg/dL (USA) and mmol/L (international). Conversion for cholesterol: 1 mmol/L ≈ 38.67 mg/dL.
- Typical targets (guideline-dependent):
- LDL-C: desirable <100 mg/dL (2.6 mmol/L); for high-risk patients (e.g., known ASCVD) many guidelines aim for <70 mg/dL (1.8 mmol/L) or lower with intensive therapy.
- HDL-C: higher is generally better; low HDL-C is <40 mg/dL (men) and <50 mg/dL (women). But HDL-C is not usually a primary treatment target — focus is on lowering LDL and reducing overall risk.
- Non-HDL and ApoB are useful when triglycerides are elevated.
Advanced/nuanced points
- Particle number vs cholesterol content: Two people can have the same LDL-C but different numbers of LDL particles. ApoB or LDL particle number (by NMR) predict risk better than LDL-C in some cases.
- Small dense LDL: more atherogenic; often associated with high TG and low HDL (atherogenic dyslipidemia), common in insulin resistance/type 2 diabetes.
- HDL functionality: antioxidant, cholesterol efflux capacity (a functional assay) may predict risk better than HDL-C level. Attempts to raise HDL-C pharmacologically have largely failed to reduce events because simply raising HDL-C does not guarantee improved function.
- Remnant cholesterol: cholesterol carried by triglyceride-rich remnants (VLDL remnants/IDL) also contributes to atherosclerosis.
- Lp(a): an LDL-like particle with an extra Apo(a) protein; genetically determined and an independent risk factor.
How drugs affect LDL and HDL (brief)
- Statins: inhibit HMG-CoA reductase → lower hepatic cholesterol synthesis → upregulate LDL receptors → lower LDL-C (primary therapy for reducing CV events).
- PCSK9 inhibitors (monoclonal antibodies, siRNA): block PCSK9-mediated LDLR degradation → more LDL receptors → large LDL-C reductions.
- Ezetimibe: reduces intestinal cholesterol absorption → lowers LDL-C (often added to statin).
- Bile acid sequestrants: lower LDL-C by interrupting bile acid reabsorption.
- Fibrates: primarily lower triglycerides and can modestly raise HDL; used for hypertriglyceridemia.
- Niacin: raises HDL-C and lowers LDL-C/TG but trials did not show consistent cardiovascular benefit when added to statins and side effects limit use.
- CETP inhibitors: raised HDL-C substantially in some cases but mostly failed to reduce events (except anacetrapib lowered events in some analyses), again highlighting HDL complexity.
Lifestyle effects
- Diet: saturated and trans fats raise LDL; replacing saturated fats with polyunsaturated fats lowers LDL. Dietary cholesterol has modest effects in most people. Reducing refined carbs and weight loss helps triglycerides and HDL.
- Exercise: aerobic exercise modestly raises HDL and improves HDL function.
- Weight loss: lowers LDL and TG and raises HDL.
- Smoking: lowers HDL and increases cardiovascular risk.
- Alcohol: moderate intake can raise HDL, but benefits are offset by other risks and not advised as a preventive strategy.
Takeaway summary
- LDL and HDL are lipoprotein particles that carry cholesterol but have very different roles: LDL delivers cholesterol (and in excess causes atherosclerosis), HDL participates in removing cholesterol and has protective functions. Cardiovascular risk is driven mainly by the number and quality of atherogenic particles (LDL, VLDL remnants, Lp[a]), with ApoB and non-HDL often better integrative measures than LDL-C alone. Clinical management focuses primarily on lowering LDL to reduce cardiovascular events; HDL-C levels are less useful as a therapeutic target than once thought because HDL function matters more than concentration.
If you want, I can:
- Explain the biochemical pathways in more molecular detail (e.g., specific enzymes, receptors and genes).
- Show how to interpret a lipid panel with example numbers.
- Summarize current guideline LDL targets for a particular risk category.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.